ROSEBUD BIOSCIENCES INC.

Biotech · Private

Automated platform for deriving patient-specific organoids from stem cells and detecting disease phenotypes using machine learning

Grants
$275K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
6
0 granted · 6 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Drug discovery using stem cell derived organoids$274,829
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3229GATACA, LLC——
3230KADVAX TECHNOLOGIES, INC.——
3231SONOVAL LLC——
3232ROSEBUD BIOSCIENCES INC.——
3233Therapeutic Vision, Inc.——
3234Florica Therapeutics, Inc.——
3235Inotrem——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 6
  • BANCR Compositions and Methods for Treating Diseaseapplication
  • Methods and Compositions for Diagnosing and Treating Rare Genetic DIseasesapplication
  • Bancr Compositions And Methods For Treating Diseaseapplication
  • Methods And Compositions For Diagnosing And Treating Rare Genetic Diseasesapplication
  • BANCR Compositions and Methods for Treating Diseaseapplication
  • Methods and Compositions for Diagnosing and Treating Rare Genetic DIseasesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.